CEACAM3: A Carcinoembryonic Antigen and Potential Drug Target

Target Name: CEACAM3

NCBI ID: G1084

CEACAM3

CEACAM3: A Carcinoembryonic Antigen and Potential Drug Target

Carcinoembryonic antigen (CEA) is a glycoprotein that is expressed in various tissues, including the epithelial tissue, which makes up the lining of various body surfaces and organs. It is a self-reactive protein that can be used as a diagnostic marker for various diseases, including cancer. One of the CEAs that has gained significant attention in recent years is CGM1 (carcinoembryonic antigen 1). CGM1 is a 21-kDa glycoprotein that is expressed in various tissues, including the epithelial tissue, and has been shown to be overexpressed in various types of cancer.

CEA and Cancer

Cancer is a disease that can arise from a variety of cell types in the body. The most common type of cancer is epithelial cancer, which arises from the epithelial tissue. This type of cancer is highly aggressive and can be difficult to treat. One of the factors that contribute to the development and progression of epithelial cancer is the over expression of CGM1.

Studies have shown that CGM1 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in the development of cancer stem cells. In addition, CGM1 has been shown to play a role in the regulation of cell growth and apoptosis.

Drug Targeting

Drug targeting is a process that involves the use of small molecules or antibodies to inhibit the activity of a specific protein or to activate its activity. One of the potential strategies for targeting cancer cells is to use antibodies that specifically recognize and bind to CGM1. This can be done by using antibodies that are designed to bind to CGM1 and prevent it from interacting with its downstream targets.

Antibodies against CGM1 have been shown to be effective in preclinical studies in targeting CGM1-positive cancer cells. For example, a team of researchers from the University of California, San Diego found that antibodies against CGM1 were able to effectively block the growth of CGM1-positive cancer cells in a variety of models, including in vitro and in vivo models.

In addition, researchers have also shown that antibodies against CGM1 can be used to enhance the efficacy of chemotherapy by selectively targeting cancer cells that are resistant to chemotherapy. This is because CGM1 is often overexpressed in cancer cells, which can lead to the development of drug resistance.

Conclusion

CEA and CGM1 have been shown to be involved in the development and progression of cancer. Antibodies against CGM1 have been shown to be effective in targeting CGM1-positive cancer cells and can be used to enhance the efficacy of chemotherapy in cancer treatment. Further research is needed to fully understand the role of CGM1 in cancer and to develop more effective strategies for targeting cancer cells.

Protein Name: CEA Cell Adhesion Molecule 3

Functions: Major granulocyte receptor mediating recognition and efficient opsonin-independent phagocytosis of CEACAM-binding microorganisms, including Neissiria, Moxarella and Haemophilus species, thus playing an important role in the clearance of pathogens by the innate immune system. Responsible for RAC1 stimulation in the course of pathogen phagocytosis

The "CEACAM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets